Archive · 16 Jan 2026
Ventura Predicts 47% Upside for Jhunjhunwala-Backed Jubilant Pharmova
Ventura Securities, a brokerage firm, thinks that Jubilant Pharmova, a company where the Jhunjhunwala family owns a big part, could see its stock price go up by 47% in the next two years.
The company is changing from just making generic medicines to being a big player in the global pharmaceutical market.
Ventura believes this is a good time for the company because of changes in the world that make it easier for them to do business.
They also think the company's focus on the US market and plans to expand will help it grow.
Ventura has set a target price of Rs 1,557 for the stock, which is much higher than its current price.
They also expect the company to make more money and reduce its debt over the next few years.
Ventura Securities predicts a 47% upside for Jubilant Pharmova stock over 24 months.
The Jhunjhunwala family holds a 6.43% stake in Jubilant Pharmova.
Ventura highlights Jubilant's strategic pivot and favorable industry trends.
The US radiopharmaceutical market is projected to grow from $5B to $20B by 2030.
Jubilant is expanding capacity to address a global sterile injectables shortfall.
- Who
- Ventura Securities, Jubilant Pharmova Ltd, Jhunjhunwala family
- What
- Ventura Securities predicts 47% upside for Jubilant Pharmova stock
- When
- Projected over the next 24 months
- Where
- India, with significant operations in the US
- Why
- Due to favorable industry trends, global geopolitical shifts, and strategic expansions
- Company
- Jubilant Pharmova Ltd
- Current Share Price
- Rs 1,059.25
- Jhunjhunwala Stake
- 6.43% (1.02 crore shares)
- Projected Upside
- 47% over 24 months
- Target Price
- Rs 1,557
- US Radiopharmaceutical Market Growth
- $5B to $20B by 2030
- Sterile Injectables Shortfall
- 700 million vials by 2027
- Revenue Growth (FY25-FY28)
- 11% CAGR
- EBITDA Growth (FY25-FY28)
- 15% CAGR
- Net Debt-to-EBITDA Ratio (FY30)
- 0.6x